Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 25, No 18S (June 20 Supplement), 2007: 4537
© 2007 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Helgason, H. H. Articles by Schellens, J. H. Search for Related Content PubMed Articles by Helgason, H. H. Articles by Schellens, J. H.

Abstract

Serum proteomic profiling of advanced gastric cancer and identification of proteomic changes following response to epirubicin, cisplatin and capecitabine chemotherapy as diagnostic and predictive biomarkers

The Netherlands Cancer Institute, Amsterdam, The Netherlands; Slotervaart Hospital, Amsterdam, The Netherlands; German Cancer Research Center, Heidelberg, Germany

4537

Background: Gastric cancer is the fourth most commonly diagnosed cancer and is the second leading cause of cancer death worldwide. Prognosis is highly dependent on stage at diagnosis making early diagnosis mandatory. By using SELDI - TOF mass spectrometry we compared serum protein profiles of gastric cancer patients with healthy controls and those of gastric cancer patients responding to first-line ECC chemotherapy with those with no response or early progressive disease. Methods: Serum from patients with advanced gastric cancer (GC) was obtained, according to a predefined schedule, prior to start of first-line epirubicin (50 mg/m² day 1), cisplatin (60 mg/m² day 1) and capecitabine (1,000 mg/m² d1–14) chemotherapy (ECC) and serially before each treatment cycle every 3 weeks and analyzed by standardized SELDI-TOF MS/MS. Serum proteomic profiles of GC patients were compared with those of matched healthy controls and proteomic profile changes in responding and non-responding patients were analyzed. Results: In total 82 patients (mean age 57 years) were treated with mean 5 ECC cycles resulting in a response rate of 35%, mean time to progression of 7.1 months and mean overall survival of 12.4 months (95% CI: 10.7 - 14.1). By comparing GC patients and healthy controls we identified 18 m/z values that significantly (p < 0.00001) differentiated between the two groups (m/z 2.7 - 66.6 kDa). Comparison of responding and non-responding patients identified 2 proteins, m/z 3109 and 7559 Da, potentially predicting response (p < 0.001). Serial analysis of proteins changing differently during chemotherapy according to response will be performed. Conclusions: We identified 18 m/z values/proteins that highly (p < 1.0 E-05) discriminated between gastric cancer patients and healthy controls serving as candidate biomarkers of gastric cancer and 2 m/z values that significantly predicted response to chemotherapy.

No significant financial relationships to disclose.

Abstract presentation from the 2007 ASCO Annual Meeting